These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 35300208)

  • 21. Systemic immune-inflammation index predicts prognosis of sequential therapy with sorafenib and regorafenib in hepatocellular carcinoma.
    Hong YM; Yoon KT; Cho M
    BMC Cancer; 2021 May; 21(1):569. PubMed ID: 34006248
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Regorafenib combined with a PD-1 inhibitor in the second-line setting for unresectable hepatocellular carcinoma in real-world practice.
    Bi H; Pei J; Ma K; Zhang Y; Aprile G; Moris D; Méndez-Sánchez N; Samant H; Sun X; Xia F
    J Gastrointest Oncol; 2024 Feb; 15(1):368-376. PubMed ID: 38482245
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pre-immunotherapy radiotherapy enhanced the efficacy of multi-line sintilimab in unresectable advanced esophageal squamous cell carcinoma.
    Xu S; Xu X; Zhu H
    Front Immunol; 2023; 14():960339. PubMed ID: 36891294
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lenvatinib plus sintilimab versus lenvatinib monotherapy as first-line treatment for advanced HBV-related hepatocellular carcinoma: A retrospective, real-world study.
    Zhao L; Chang N; Shi L; Li F; Meng F; Xie X; Xu Z; Wang F
    Heliyon; 2022 Jun; 8(6):e09538. PubMed ID: 35706954
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Regorafenib combined with sintilimab as second-line treatment for advanced HCC patient: a case report.
    Wan Y; Zhu H
    Front Oncol; 2023; 13():1256137. PubMed ID: 37881484
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Regorafenib in patients with advanced Child-Pugh B hepatocellular carcinoma: A multicentre retrospective study.
    Kim HD; Bang Y; Lee MA; Kim JW; Kim JH; Chon HJ; Kang B; Kang MJ; Kim I; Cheon J; Hwang JE; Kang JH; Byeon S; Hong JY; Ryoo BY; Lim HY; Yoo C
    Liver Int; 2020 Oct; 40(10):2544-2552. PubMed ID: 32563213
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multicenter retrospective analysis of the safety and efficacy of regorafenib after progression on sorafenib in Korean patients with hepatocellular carcinoma.
    Yoo C; Park JW; Kim YJ; Kim DY; Yu SJ; Lim TS; Lee SJ; Ryoo BY; Lim HY
    Invest New Drugs; 2019 Jun; 37(3):567-572. PubMed ID: 30523474
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Study on safety and efficacy of regorafenib combined with transcatheter arterial chemoembolization in the treatment of advanced hepatocellular carcinoma after first-line targeted therapy.
    Wang H; Xiao W; Han Y; Cao S; Zhang Z; Chen G; Hu Y; Jin L
    J Gastrointest Oncol; 2022 Jun; 13(3):1248-1254. PubMed ID: 35837179
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical Study of Sintilimab as Second-Line or Above Therapy in Patients With Advanced or Metastatic Gastric Cancer: A Retrospective Study.
    Nie C; Lv H; Liu Y; Chen B; Xu W; Wang J; Chen X
    Front Oncol; 2021; 11():741865. PubMed ID: 34631579
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of sintilimab in combination with chemotherapy for recurrent extensive-stage small cell lung cancer: a real-world retrospective study.
    Wang J; Liang S; Xu L; Kong Y; Seki N; Ganti AK; Neal JW; Li J; Xu F; Li K; Xu Y; Wu L; Chen B
    J Thorac Dis; 2024 Jun; 16(6):3897-3908. PubMed ID: 38983156
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A retrospective cohort study of sintilimab and pembrolizumab as first-line treatments for advanced non-small cell lung cancer.
    Wu K; Fu Y; Zeng D; Chen T; Wang C; Jiang J
    J Thorac Dis; 2022 Mar; 14(3):679-688. PubMed ID: 35399230
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of the efficacy and safety of fruquintinib and regorafenib in the treatment of metastatic colorectal cancer: A real-world study.
    Deng YY; Zhang XY; Zhu PF; Lu HR; Liu Q; Pan SY; Chen ZL; Yang L
    Front Oncol; 2023; 13():1097911. PubMed ID: 36937443
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of regorafenib as second-line treatment for patients with hepatocellular carcinoma and macrovascular invasion and(or) extrahepatic metastasis.
    Zhao Y; Liu W; Zheng L; Goyal S; Awosika J; Wang H; Yang S
    J Gastrointest Oncol; 2023 Dec; 14(6):2536-2548. PubMed ID: 38196538
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of regorafenib in the second-and third-line setting for patients with advanced hepatocellular carcinoma: A real life data of multicenter study from Turkey.
    Bekir Hacioglu M; Kostek O; Karabulut S; Tastekin D; Sezgin Goksu S; Alandag C; Akagunduz B; Bilgetekin I; Caner B; Bilgehan Sahin A; Yildiz B; Kose F; Kaplan MA; Gulmez A; Dogan E; Can Guven D; Gurbuz M; Ergun Y; Karaagac M; Gokcen Demiray A; Turker S; Sakalar T; Ozkul O; Telli TA; Sahin S; Kilickap S; Bilici A; Erdogan B; Cicin I
    J BUON; 2020; 25(4):1897-1903. PubMed ID: 33099930
    [TBL] [Abstract][Full Text] [Related]  

  • 35. On-Treatment Albumin-Bilirubin Grade: Predictor of Response and Outcome of Sorafenib-Regorafenib Sequential Therapy in Patients with Unresectable Hepatocellular Carcinoma.
    Wang HW; Chuang PH; Su WP; Kao JT; Hsu WF; Lin CC; Huang GT; Lin JT; Lai HC; Peng CY
    Cancers (Basel); 2021 Jul; 13(15):. PubMed ID: 34359658
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Real-world systemic sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Korea.
    Lee MJ; Chang SW; Kim JH; Lee YS; Cho SB; Seo YS; Yim HJ; Hwang SY; Lee HW; Chang Y; Jang JY
    Invest New Drugs; 2021 Feb; 39(1):260-268. PubMed ID: 32749658
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The prognostic role of neutrophil-to-lymphocyte ratio and C-reactive protein in metastatic colorectal cancer using regorafenib: a systematic review and meta-analysis.
    Zhao N; Xu H; Zhou D; Xu X; Ge W; Cao D
    J Gastrointest Oncol; 2022 Aug; 13(4):1772-1781. PubMed ID: 36092324
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and Efficacy of Sintilimab and Anlotinib as First Line Treatment for Advanced Hepatocellular Carcinoma (KEEP-G04): A Single-Arm Phase 2 Study.
    Chen X; Li W; Wu X; Zhao F; Wang D; Wu H; Gu Y; Li X; Qian X; Hu J; Li C; Xia Y; Rao J; Dai X; Shao Q; Tang J; Li X; Shu Y
    Front Oncol; 2022; 12():909035. PubMed ID: 35712486
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Study on efficacy and safety of transcatheter arterial chemoembolization (TACE) combined with regorafenib and PD-1 antibody versus continued TACE combined with regorafenib in patients with hepatocellular carcinoma after failed second-line treatment with regorafenib.
    Wang H; Xiao W; Han Y; Cao S; Zhang Z; Chen G; Hu Y; Jin L
    J Gastrointest Oncol; 2022 Aug; 13(4):1907-1914. PubMed ID: 36092351
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and Safety of Regorafenib Combined with Toripalimab in the Third-Line and beyond Treatment of Advanced Colorectal Cancer.
    Yu W; Tao Q; Zhang Y; Yi F; Feng L
    J Oncol; 2021; 2021():9959946. PubMed ID: 34603452
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.